Drug Profile
Research programme: nuclear export inhibitors - Kosan
Alternative Names: CRM1 inhibitors - Kosan; KOS 2464; KOS-1815; KOS-2385Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Kosan Biosciences
- Class
- Mechanism of Action Exportin-1 protein inhibitors; Nuclear export inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (IV)
- 27 Jun 2008 Kosan Biosciences has been acquired by Bristol-Myers Squibb
- 10 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the pharmacokinetics, adverse events and Cancer pharmacodynamics section ,